In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases
This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.
Projectdetails
Introduction
Genetic brain diseases are among the most devastating and fatal diseases, typically having only palliative treatments and no cure. The revolutionary CRISPR/Cas gene editing technology provides a new horizon and enormous potential for treating such diseases.
Challenge of Delivery
However, efficient and safe delivery of CRISPR machinery to diseased cells within the brain is one of the greatest challenges in medicine today. Here, I plan to expand far beyond the state-of-the-art and propose a game-changing approach for this unmet need: a breakthrough nanoplatform, which will transform CRISPR into a clinically relevant, non-invasive technology, enabling therapeutic genome editing in the brain.
Proof-of-Concept Results
Our proof-of-concept results serve as the baseline of this pioneering research project, revealing the exceptional capabilities of insulin as a key to overcoming formidable brain and cell barriers. We will harness these unique abilities within the novel nanoplatform, and:
- Shuttle CRISPR machinery across the blood-brain barrier
- Transport it into deep brain regions
- Mediate its successful entry into specific diseased brain cells, leading to highly effective gene editing.
Design Criteria
The nanoplatform will be designed to meet key criteria for non-invasive, safe, and efficient delivery of CRISPR to the brain, while conferring a high degree of modularity and compositional heterogeneity. This will provide both universal and patient-specific components.
Research Methodology
The nanoplatform will be thoroughly investigated in:
- Primary brain cells
- 3D organoids
- Case studies of monogenic brain disease models
Conclusion
This comprehensive research will culminate with a universal and modular BrainCRISPR nanoplatform, and delineate design principles for its precise tailoring to the specific needs of different brain diseases. Overall, this research will provide in-depth fundamental knowledge and have a transformative effect on applying CRISPR in the brain, whilst opening a wide array of possibilities with broader impact on genetic brain therapy and beyond.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.249.895 |
Totale projectbegroting | € 2.249.895 |
Tijdlijn
Startdatum | 1-6-2022 |
Einddatum | 31-5-2027 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- BAR ILAN UNIVERSITYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Profile nucleases and Repurpose Off-Targets to Expand Gene EditingThe PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies. | ERC Starting... | € 1.141.779 | 2023 | Details |
A novel and empowered TARGETed gene addition approach at a relevant microglia locus for the treatment of inherited NeuroMetabolic DiseasesDevelop a targeted gene addition approach at a microglia locus in HSCs to safely and effectively treat inherited neurometabolic diseases by enhancing timely microglia-like cell engraftment. | ERC Advanced... | € 2.495.250 | 2022 | Details |
Harnessing a novel CRISPR nuclease for programmable counterselection in human cellsThis project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications. | ERC Proof of... | € 150.000 | 2024 | Details |
4D Brain-Targeting Nanomedicines for Treating NeurodegenerationThis project aims to develop advanced 4D-brain-targeting nanoparticles using nanotechnology to effectively deliver treatments for neurodegenerative diseases across the blood-brain barrier. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Transcriptional Engineering of Hematopoietic Stem Cells using CRISPRThis project aims to enhance hematopoietic stem cell therapies by using repurposed CRISPR/Cas systems for precise transcriptional manipulation of key genetic pathways. | ERC Starting... | € 1.499.923 | 2022 | Details |
Profile nucleases and Repurpose Off-Targets to Expand Gene Editing
The PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies.
A novel and empowered TARGETed gene addition approach at a relevant microglia locus for the treatment of inherited NeuroMetabolic Diseases
Develop a targeted gene addition approach at a microglia locus in HSCs to safely and effectively treat inherited neurometabolic diseases by enhancing timely microglia-like cell engraftment.
Harnessing a novel CRISPR nuclease for programmable counterselection in human cells
This project aims to enhance CRISPR genome editing efficiency by developing a programmable counter-selection mechanism to eliminate unedited cells, thereby reducing screening burdens in various applications.
4D Brain-Targeting Nanomedicines for Treating Neurodegeneration
This project aims to develop advanced 4D-brain-targeting nanoparticles using nanotechnology to effectively deliver treatments for neurodegenerative diseases across the blood-brain barrier.
Transcriptional Engineering of Hematopoietic Stem Cells using CRISPR
This project aims to enhance hematopoietic stem cell therapies by using repurposed CRISPR/Cas systems for precise transcriptional manipulation of key genetic pathways.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
New Prime Editing and non-viral delivery strategies for Gene TherapyThis project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders. | EIC Pathfinder | € 4.406.097 | 2022 | Details |
Next generation gene writing platform to cure genetic and oncological diseasesIntegra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases. | EIC Accelerator | € 2.496.375 | 2024 | Details |
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATIONREGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration. | EIC Pathfinder | € 2.943.233 | 2024 | Details |
FluEdit: Microfluidics Gen-editing platform voor bloedcellenNTrans Technologies ontwikkelt het Flu-Edit platform om efficiënt en veilig gen-editing therapieën voor bloedziekten te realiseren met behulp van microfluidics en iTOP technologie. | Mkb-innovati... | € 20.000 | 2023 | Details |
NOn-VIral gene modified STEM cell therapyThis project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application. | EIC Pathfinder | € 3.644.418 | 2022 | Details |
New Prime Editing and non-viral delivery strategies for Gene Therapy
This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.
Next generation gene writing platform to cure genetic and oncological diseases
Integra Therapeutics' FiCAT platform enhances gene therapy by enabling precise and safe insertion of large DNA sequences, aiming to cure genetic and cancer-related diseases.
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION
REGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration.
FluEdit: Microfluidics Gen-editing platform voor bloedcellen
NTrans Technologies ontwikkelt het Flu-Edit platform om efficiënt en veilig gen-editing therapieën voor bloedziekten te realiseren met behulp van microfluidics en iTOP technologie.
NOn-VIral gene modified STEM cell therapy
This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.